NASDAQ:ATRC

AtriCure Competitors

Top-Rated Stocks

$43.24

+0.78 (+1.84 %)

(As of 11/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$42.15

Now: $43.24▼

$43.84

50-Day Range

$34.56

MA: $38.92▼

$42.84

52-Week Range

$23.17

Now: $43.24▼

$51.76

Volume379,643 shs

Average Volume412,681 shs

Market Capitalization$1.95 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.92

AtriCure (NASDAQ:ATRC) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ATRC stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to AtriCure, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

AtriCure vs. Abbott Laboratories Stock

Abbott Laboratories (NYSE:ABT) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Abbott Laboratories and AtriCure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	10.50%	18.19%	8.29%
AtriCure	-21.74%	-14.83%	-7.77%

Risk & Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 5.8% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and AtriCure's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$31.90 billion	6.07	$3.69 billion	$3.24	33.73
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41

Abbott Laboratories has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abbott Laboratories and AtriCure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	1	4	13	0	2.67
AtriCure	0	0	7	0	3.00

Abbott Laboratories presently has a consensus price target of $115.3750, indicating a potential upside of 5.59%. AtriCure has a consensus price target of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats AtriCure on 8 of the 14 factors compared between the two stocks.

AtriCure vs. Medtronic Stock

Medtronic (NYSE:MDT) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Medtronic and AtriCure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medtronic	15.80%	10.47%	5.80%
AtriCure	-21.74%	-14.83%	-7.77%

Volatility and Risk

Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Medtronic and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$28.91 billion	5.16	$4.79 billion	$4.59	24.18
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41

Medtronic has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medtronic and AtriCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	1	3	20	1	2.84
AtriCure	0	0	7	0	3.00

Medtronic presently has a consensus target price of $118.1538, indicating a potential upside of 6.47%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Medtronic.

Summary

Medtronic beats AtriCure on 9 of the 15 factors compared between the two stocks.

AtriCure vs. Stryker Stock

Stryker (NYSE:SYK) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Stryker and AtriCure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stryker	11.38%	20.53%	8.89%
AtriCure	-21.74%	-14.83%	-7.77%

Volatility and Risk

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Stryker and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$14.88 billion	5.88	$2.08 billion	$8.26	28.21
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41

Stryker has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Stryker and AtriCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	2	9	15	1	2.56
AtriCure	0	0	7	0	3.00

Stryker presently has a consensus target price of $221.44, indicating a potential downside of 4.97%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Stryker.

Summary

Stryker beats AtriCure on 10 of the 15 factors compared between the two stocks.

AtriCure vs. Intuitive Surgical Stock

Intuitive Surgical (NASDAQ:ISRG) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Intuitive Surgical and AtriCure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	24.45%	12.08%	10.44%
AtriCure	-21.74%	-14.83%	-7.77%

Volatility and Risk

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Intuitive Surgical and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$4.48 billion	18.87	$1.38 billion	$9.95	72.27
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41

Intuitive Surgical has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Intuitive Surgical and AtriCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	3	7	12	0	2.41
AtriCure	0	0	7	0	3.00

Intuitive Surgical presently has a consensus target price of $718.2778, indicating a potential downside of 0.11%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats AtriCure on 10 of the 14 factors compared between the two stocks.

AtriCure vs. Becton, Dickinson and Stock

AtriCure (NASDAQ:ATRC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

88.6% of AtriCure shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares AtriCure and Becton, Dickinson and's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41
Becton, Dickinson and	$17.12 billion	3.87	$874 million	$10.20	22.40

Becton, Dickinson and has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for AtriCure and Becton, Dickinson and, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0	0	7	0	3.00
Becton, Dickinson and	0	7	7	1	2.60

AtriCure currently has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts clearly believe AtriCure is more favorable than Becton, Dickinson and.

Profitability

This table compares AtriCure and Becton, Dickinson and's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	-21.74%	-14.83%	-7.77%
Becton, Dickinson and	5.11%	13.30%	5.60%

Volatility and Risk

AtriCure has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats AtriCure on 8 of the 14 factors compared between the two stocks.

AtriCure vs. Edwards Lifesciences Stock

AtriCure (NASDAQ:ATRC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

88.6% of AtriCure shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares AtriCure and Edwards Lifesciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$230.81 million	8.43	$-35,190,000.00	($1.07)	-40.41
Edwards Lifesciences	$4.35 billion	12.14	$1.05 billion	$1.86	45.54

Edwards Lifesciences has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for AtriCure and Edwards Lifesciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0	0	7	0	3.00
Edwards Lifesciences	2	5	13	0	2.55

AtriCure currently has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts clearly believe AtriCure is more favorable than Edwards Lifesciences.

Profitability

This table compares AtriCure and Edwards Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	-21.74%	-14.83%	-7.77%
Edwards Lifesciences	18.18%	29.00%	18.10%

Volatility and Risk

AtriCure has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats AtriCure on 9 of the 13 factors compared between the two stocks.